VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH CML 2022 | The importance of better selecting patients with CML who are eligible for treatment discontinuation

Susanne Saussele, MD, University of Heidelberg, Mannheim, Germany, emphasizes the importance of better defining criteria for patient selection for treatment discontinuation in chronic myeloid leukemia (CML) to improve treatment-free remission (TFR) success and quality of life (QoL). This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


BMS, Incyte, Novartis, Honoraria: BMS, Incyte, Novartis, Pfizer, Roche

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter